Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) shares were down 6.5% during trading on Thursday . The company traded as low as $0.43 and last traded at $0.43. Approximately 876,853 shares changed hands during mid-day trading, an increase of 34% from the average daily volume of 655,875 shares. The stock had previously closed at $0.46.
A number of research analysts have recently commented on PLX shares. HC Wainwright set a $4.00 price target on Protalix Biotherapeutics and gave the company a “buy” rating in a research note on Thursday, December 13th. Zacks Investment Research raised Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 21st.
A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC grew its holdings in Protalix Biotherapeutics by 44.4% during the 4th quarter. Virtu Financial LLC now owns 91,862 shares of the company’s stock worth $29,000 after acquiring an additional 28,236 shares during the period. Renaissance Technologies LLC grew its stake in shares of Protalix Biotherapeutics by 24.9% in the 3rd quarter. Renaissance Technologies LLC now owns 3,266,401 shares of the company’s stock valued at $2,374,000 after buying an additional 651,701 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of Protalix Biotherapeutics in the 3rd quarter valued at about $1,881,000.
TRADEMARK VIOLATION WARNING: “Protalix Biotherapeutics (PLX) Stock Price Down 6.5%” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2019/03/14/protalix-biotherapeutics-plx-stock-price-down-6-5.html.
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.